British drugmaker GlaxoSmithKline is investing $95 million to create a new U.S. research institute led by a top genomics professor to investigate how a cell's operating system works.
The move reflects a commitment to fundamental research by the British company, even as its shifts emphasis to greater reliance on non-pharmaceutical businesses such as consumer healthcare and vaccines.
